Lupin receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-2 manufacturing facility that manufactures oral solids and ophthalmic dosage forms. The EIR was issued post the last inspection of the facility conducted from March 21 to March 29, 2023. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

"We are pleased to have received the EIR from the US FDA with a satisfactory VAI status for our Pithampur Unit-2 facility. This is a significant milestone as we build back our reputation of being bestin-class in Quality and Compliance. We look forward to new products approvals and launches, especially ophthalmic products from this facility now," said Nilesh Gupta, Managing Director, Lupin.

Shares of Lupin Limited was last trading in BSE at Rs. 912.90 as compared to the previous close of Rs. 900.70. The total number of shares traded during the day was 24609 in over 1323 trades.

The stock hit an intraday high of Rs. 919.65 and intraday low of 900.05. The net turnover during the day was Rs. 22418551.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA EIR Pithampur Unit2 ManufacturingFacility